All sponsors

BioInvent International AB

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS5
PHASE 3 / 2-30
RECRUITING3
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO60%

Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +38.0 months). See all sponsors →

Open BioInvent International AB on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
pembrolizumab (KEYTRUDA®)
NCT06784648
P1/2Active, not recruitingMelanoma Metastatic; Melanoma of Skin352026-09-09 (-25 mo)
BI-1910
NCT06205706
P1/2Active, not recruitingSolid Tumors; Non Small Cell Lung Cancer352027-07-14
BI-1206
NCT03571568
P1/2RecruitingIndolent B-Cell Non-Hodgkin Lymphoma1402027-09-30 (+87 mo)
BI1206
NCT04219254
P1/2RecruitingSolid Tumor, Adult1972027-11 (+42 mo)
BI-1808
NCT04752826
P1/2RecruitingAdvanced Malignancies; Ovarian Cancer2502028-01-31 (+38 mo)